The expression of various glioma stemness markers – NANOG (4-fold increase), SOX2 (3-fold increase), SOX2-OT (15-fold increase) and CD133 (3-fold increase) – were also significantly increased in high-grade glioma samples compared to the controls (Fig. 2A). This evidence concerns the gene OXT and central nervous system cancer.